CLIN.L - Clinigen Group Plc
| Previous close | 820.00 |
| Open | 830.00 |
| Bid | 852.50 x 0 |
| Ask | 854.00 x 0 |
| Day's range | 810.00 - 870.50 |
| 52-week range | 350.40 - 1,052.00 |
| Volume | 519,819 |
| Avg. volume | 606,638 |
| Market cap | 1.127B |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | 81.54 |
| EPS (TTM) | 10.40 |
| Earnings date | 25 Feb 2020 |
| Forward dividend & yield | 0.07 (0.84%) |
| Ex-dividend date | 19 Mar 2020 |
| 1y target est | 1,259.67 |
- Simply Wall St.
Are Clinigen Group plc's (LON:CLIN) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
It is hard to get excited after looking at Clinigen Group's (LON:CLIN) recent performance, when its stock has declined...
- Stockopedia
The Clinigen share price – where next?
The Clinigen (LON:CLIN) share price has risen by 18.8% over the past month and it’s currently trading at 707.5. For investors considering whether to buy, hold...
- Business Wire
Clinigen: IL-2 Plays Role in Emerging TIL Therapies
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company acknowledges the presentation of results from the Phase I trial "Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non -small cell lung cancer (NSCLC)." Ben C. Creelan MD, MS from the Thoracic Oncology, Immunology Program of the Moffitt Cancer and Research Institute presented at the American Association for Cancer Research (AACR) virtual annual meeting on April 28, 2020. Eligibility criteria described in trial registry (NCT03215810).
- Stockopedia
Upbeat broker recommendations for Clinigen
The Clinigen (LON:CLIN) share price has risen by 39.1% over the past month and it’s currently trading at 719.095. For investors considering whether to buy, hol8230;
- Simply Wall St.
A Rising Share Price Has Us Looking Closely At Clinigen Group plc's (LON:CLIN) P/E Ratio
Clinigen Group (LON:CLIN) shareholders are no doubt pleased to see that the share price has bounced 47% in the last...
- Simply Wall St.
Is Now An Opportune Moment To Examine Clinigen Group plc (LON:CLIN)?
Clinigen Group plc (LON:CLIN), which is in the life sciences business, and is based in United Kingdom, saw a...
- Simply Wall St.
Does Clinigen Group's (LON:CLIN) Share Price Gain of 89% Match Its Business Performance?
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
- Simply Wall St.
How Much is Clinigen Group plc's (LON:CLIN) CEO Getting Paid?
In 2016 Shaun Chilton was appointed CEO of Clinigen Group plc (LON:CLIN). This analysis aims first to contrast CEO...
- Simply Wall St.
Clinigen Group plc (LON:CLIN) Delivered A Weaker ROE Than Its Industry
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- Simply Wall St.
Are Investors Undervaluing Clinigen Group Plc (LON:CLIN) By 41%?
How far off is Clinigen Group Plc (LON:CLIN) from its intrinsic value? Using the most recent financial data, we'll...
- Simply Wall St.
Is Clinigen Group (LON:CLIN) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Simply Wall St.
How Many Clinigen Group Plc (LON:CLIN) Shares Did Insiders Buy, In The Last Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- Simply Wall St.
Why Clinigen Group Plc's (LON:CLIN) High P/E Ratio Isn't Necessarily A Bad Thing
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it...
- Simply Wall St.
I Ran A Stock Scan For Earnings Growth And Clinigen Group (LON:CLIN) Passed With Ease
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
